GLP-1 news moves fast: new approvals, big studies, recalls, pricing changes. Instead of chasing headlines all over the internet, you can find them right here, explained in plain language.

Here's how it works:
• Breaking news: When something big happens, we'll post a full write-up on the blog and drop the link in this thread.
• Friday roundup: Every Friday, we wrap up the week's top stories in one easy read.
• Your take: Reply to any update with your questions, reactions and "wait, what does that mean?" moments. That's what this thread is for!

Spotted a story we missed? Share the link below (reputable sources, please 🙏).

A friendly reminder: we share news, not medical advice. For anything about your own treatment, your doctor or pharmacist is the best person to ask.

📌 This week's roundup: Weekly GLP-1 News Roundup (Oct 23)

So, which headline has you talking this week? 👇

— The Tideflock team

This is a place for people taking GLP-1 medications like Ozempic, Wegovy, Mounjaro, Zepbound, or compounded semaglutide or tirzepatide. Maybe you're thinking about starting, maybe you took your first dose this morning, or maybe you've been at it for a year. Whatever brought you here, you belong.

A few things to get you settled:

• Read the Community Guidelines. They're short. The big ones: be kind, no shaming of bodies or choices, no buying or selling medication, and nothing here replaces your prescriber.
• Pick a nickname. Your privacy matters. You don't need to use your real name.
• Say hello in Introduce Yourself. Share as much or as little as you like.
• Ask anything. No question is too basic. Someone here has probably wondered the same thing.

Tideflock is a free iOS app for tracking doses, estimated medication levels, weight, and side effects. It's still in development and coming soon. If you have ideas for it, the Feedback and Feature Requests forum is the place to share them.

Questions about the site? Email support@tideflock.app.

Track your journey. Join the flock.